Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSX-011 Dose Response and PK in Hypogonadal Males
NCT03335254Phase 2Terminated
- Sponsor
- TesoRx Pharma
- Start
- Nov 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSX-011 in male hypogonadism, sponsored by TesoRx Pharma. Started Nov 2017; status: terminated.
02
Drugs
TSX-011
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT03335254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335254.